Der Nuklearmediziner 2014; 37(02): 77-82
DOI: 10.1055/s-0034-1370978
MRT für Nuklearmediziner
© Georg Thieme Verlag KG Stuttgart · New York

MRT-Diagnostik des Prostatakarzinoms

MR Imaging of Prostate Cancer
A. Wetter
1   Institut für diagnostische und interventionelle Radiologie und Neuroradiologie, Universitätsklinikum Essen
,
T. C. Lauenstein
1   Institut für diagnostische und interventionelle Radiologie und Neuroradiologie, Universitätsklinikum Essen
› Author Affiliations
Further Information

Publication History

Publication Date:
07 July 2014 (online)

Zusammenfassung

Dieser Übersichtsartikel behandelt die MRT-Diagnostik des Prostatakarzinoms. Technische Grundlagen der MRT beim Prostatakarzinom werden dargestellt. Die verwendeten MR-Sequenzen der multiparametrischen Prostata-MRT werden erläutert und im Kontext der aktuellen Literatur dargestellt. Als Ausblick behandelt ein Kapitel die neue Methode der simultanen PET/MRT beim Prostatakarzinom.

Abstract

This review article covers MRI diagnostics in prostate carcinoma. Technical fundamentals of MRI in prostate cancer are illustrated. The employed MR sequences of multi-parametric MRI are exemplified and presented in the context of the current literature. As a perspective, one chapter is dealing with the new method of simultaneous PET-MRI in prostate cancer.

 
  • Literatur

  • 1 Abd-Alazeez M, Kirkham A, Ahmed HU et al. Performance of multiparametric MRI in men at risk of prostate cancer before the first biopsy: a paired validating cohort study using template prostate mapping biopsies as the reference standard. Prostate Cancer Prostatic Dis 2013; DOI: 10.1038/pcan.2013.43. [Epub ahead of print]
  • 2 Afshar-Oromieh A, Malcher A, Eder M et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging; 2013. 40. 486-495 Erratum in: Eur J Nucl Med MOl Imaging. 2013 40 797-798
  • 3 Akin O, Sala E, Moskowitz CS et al. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology 2006; 239: 784-792
  • 4 Arnold M, Karim-Kos HE, Coebergh JW et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. Eur J Cancer 2013; pii: S0959-8049(13)00842-3 DOI: 10.1016/j.ejca.2013.09.002. [Epub ahead of print]
  • 5 Barentsz JO, Richenberg J, Clements R et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012; 22: 746-757
  • 06 Borren A, Moman MR, Groenendaal G et al. Why prostate tumour delineation based on apparent diffusion coefficient is challenging: an exploration of the tissue microanatomy. Acta Oncol 2013; 52: 1629-1636
  • 7 Challapalli A, Barwick T, Tomasi G et al. Exploring the potential of [11C]choline-PET/CT as a novel imaging biomarker for predicting early treatment response in prostate cancer. Nucl Med Commun 2014; 35: 20-29
  • 8 Cruz M, Tsuda K, Narumi Y et al. Characterization of low-intensity lesions in the peripheral zone of prostate on pre-biopsy endorectal coil MR imaging. Eur Radiol 2002; 12: 357-365
  • 9 Delongchamps NB, Beuvon F, Eiss D et al. Multiparametric MRI is helpful to predict tumor focality, stage, and size in patients diagnosed with unilateral low-risk prostate cancer. Prostate Cancer Prostatic Dis 2011; 14: 232-237
  • 10 Desouza NM, Riches SF, Vanas NJ et al. Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer. Clin Radiol 2008; 63: 774-782
  • 11 Engelbrecht MR, Huisman HJ, Laheij RJ et al. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 2003; 229: 248-254
  • 12 Fütterer JJ, Heijmink SW, Scheenen TW et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006; 241: 449-458
  • 13 Haider MA, Van Der Kwast TH, Tanguay J et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol 2007; 189: 323-328
  • 14 Hambrock T, Somford DM, Huisman HJ et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 2011; 259: 453-461
  • 15 Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. AWMF-Registernummer (043-022OL)
  • 16 Jung JA, Coakley FV, Vigneron DB et al. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology 2004; 233: 701-708
  • 17 Kim CK, Park BK, Lee HM et al. Value of diffusion-weighted imaging for the prediction of prostate cancer location at 3T using a phased-array coil: preliminary results. Invest Radiol 2007; 42: 842-847
  • 18 Kitajima K, Kaji Y, Fukabori Y et al. Prostate cancer detection with 3 T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. J Magn Reson Imaging 2010; 31: 625-631
  • 19 Kurhanewicz J, Vigneron DB, Hricak H et al. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24–0.7-cm3) spatial resolution. Radiology 1996; 198: 795-805
  • 20 Kuru TH, Roethke MC, Rieker P et al. Histology core-specific evaluation of the European Society of Urogenital Radiology (ESUR) standardised scoring system of multiparametric magnetic resonance imaging (mpMRI) of the prostate. BJU Int 2013; 112: 1080-1087
  • 21 Margel D, Yap SA, Lawrentschuk N et al. Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study. J Urol 2012; 187: 1247-1252
  • 22 Nagel KN, Schouten MG, Hambrock T et al. Differentiation of prostatitis and prostate cancer by using diffusion-weighted MR imaging and MR-guided biopsy at 3 T. Radiology 2013; 267: 164-172
  • 23 Oto A, Kayhan A, Jiang Y et al. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology 2010; 257: 715-723
  • 24 Portalez D, Mozer P, Cornud F et al. Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. Eur Urol 2012; 62: 986-996
  • 25 Puech P, Potiron E, Lemaitre L et al. Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens. Urology 2009; 74: 1094-1099
  • 26 Røe K, Kakar M, Seierstad T et al. Early prediction of response to radiotherapy and androgen-deprivation therapy in prostate cancer by repeated functional MRI: a preclinical study. Radiat Oncol 2011; 6: 65
  • 27 Roebuck JR, Haker SJ, Mitsouras D et al. Carr-Purcell-Meiboom-Gill imaging of prostate cancer: quantitative T2 values for cancer discrimination. Magn Reson Imaging 2009; 27: 497-502
  • 28 Scherr MK, Seitz M, Muller-Lisse U et al. MR-perfusion (MRP) and diffusion-weighted imaging (DWI) in prostate cancer: quantitative and model-based gadobenate dimeglumine MRP parameters in detection of prostate cancer. Eur J Radiol 2010; 76: 359-366
  • 29 Shukla-Dave A, Hricak H, Eberhardt SC et al. Chronic prostatitis: MR imaging and 1H MR spectroscopic imaging findings – initial observations. Radiology 2004; 231: 717-724
  • 30 Tamada T, Sone T, Higashi H et al. Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4–10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging. AJR 2011; 197: 664-670
  • 31 Turkbey B, Mani H, Shah V et al. Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol 2011; 186: 1818-1824
  • 32 Villeirs GM, De Meerleer GO, De Visschere PJ et al. Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: a single-institution experience of 356 patients. Eur J Radiol 2011; 77: 340-345
  • 33 Wetter A, Lipponer C, Nensa F et al. Simultaneous 18F choline positron emission tomography/magnetic resonance imaging of the prostate: initial results. Invest Radiol 2013; 48: 256-262
  • 34 Wetter A, Lipponer C, Nensa F et al. Evaluation of the PET component of simultaneous [(18)F]choline PET/MRI in prostate cancer: comparison with [(18)F]choline PET/CT. Eur J Nucl Med Mol Imaging 2014; 41: 79-88
  • 35 Yu KK, Hricak H, Alagappan R et al. Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis. Radiology 1997; 202: 697-702